Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 17;10:855097. doi: 10.3389/fcell.2022.855097

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 De Ieso, Kuhn, Bernatchez, Elliott and Stamer.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Cellular localization of RhoA in Cav1-competent and Cav1-deficient human TM cells. ((A), Top) Under basal conditions, Cav1 protein localized almost exclusively to membrane fraction in TM cells (250-fold, ****p < 0.0001, paired t-test, n = 6 experiments using five different TM cell strains). ((A), Bottom) Representative blots from a hTM cell strain depicting Cav1 signal in cytosolic verses membrane fractions, normalized to total protein. ((B), Top) For the membrane fraction only, Cav1 protein levels were significantly decreased by approximately 53% in cells treated with CAV1-silencing shRNA compared to cells treated with scrambled shRNA (**p = 0.001, paired t-test, n = 6 experiments using five different human TM cell strains). ((B), Bottom) Representative blots from an hTM cell strain depicting membrane-bound Cav1 protein abundance, normalized to total protein. ((C), Top) Under basal conditions, α-tubulin protein localized preferentially to the cytosolic fraction in TM cells (5.5-fold, *p = 0.012, paired t-test, n = 6 experiments using five different TM cell strains). ((C), Bottom) Representative blots from a hTM cell strain depicting α-tubulin signal in cytosolic verses membrane fractions, normalized to total protein. ((D), Top) Under basal conditions, RhoA protein localized preferentially to the membrane fraction (5-fold) as compared to cytosolic fraction (****p < 0.0001, paired t-test, n= 6 experiments using five different TM cell strains). ((D), Bottom) Representative blots from a hTM cell strain depicting RhoA signal in cytosolic verses membrane fractions, normalized to total protein. ((E), Top) For the membrane fraction only, RhoA protein levels were not significantly different in cells treated with CAV1-silencing shRNA compared to cells treated with scrambled shRNA (p = 0.13, paired t-test, n = 6 experiments using five different human TM cell strains). ((E), Bottom) Representative blots from a hTM cell strain depicting membrane-bound RhoA protein abundance, normalized to total protein. ((F), Top) For the cytosolic fraction only, RhoA protein levels were significantly decreased by approximately 38% in cells treated with CAV1-silencing shRNA compared to cells treated with scrambled shRNA (***p = 0.0004, paired t-test, n = 6 experiments using five different human TM cell strains). ((F), Bottom) Representative blots from an hTM cell strain depicting cytosolic RhoA protein abundance, normalized to total protein.